News & Updates

Adding the anti-PD-1 monoclonal antibody tislelizumab to chemotherapy in the first-line treatment of PD-1-positive advanced gastric or gastroesophageal junction adenocarcinoma appears to produce significant and clinically meaningful improvements in survival outcomes while having an acceptable safety profile, according to interim data from the phase III RATIONALE 305 trial.

Treatment with the dual PPAR α/γ agonist saroglitazar helps improve the serum atherogenic lipoprotein profile in patients with nonalcoholic fatty liver disease (NAFLD), regardless of comorbid conditions and statin use, as shown in a study.

Long-acting injectable antipsychotics (LAIAs) showed no substantial advantage over oral antipsychotics in terms of time to discontinuation in patients with early-phase schizophrenia, the EULAST trial has demonstrated.

Treatment with single fraction radiation therapy (RT) results in lesser hepatic pain in most patients with end-stage hepatocellular carcinoma (HCC) or liver metastases, according to a study presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).

Men with urologic chronic pelvic pain syndrome (UCPPS) tend to suffer a more severe sexual dysfunction, including erectile (ED) and ejaculatory dysfunction, when compared to their healthy counterparts or patients with other chronic pain conditions, reveals a study.

Increased consumption of plant-based foods is associated with a lower risk of developing colorectal cancer (CRC) in men, according to the Multiethnic Cohort study.

Giving chemotherapy to patients with synchronous and unresectable liver metastases from colorectal cancer before undergoing primary tumour resection helps boost survival outcomes, according to a phase III trial presented at this year’s ASCO Gastrointestinal Cancer Symposium (ASCO GI).